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Abstract Platelet-associated Bruton’s tyrosine kinase (Btk)
was completely cleaved if treated with calcium ionophore A23187
with appearance of a proteolytic product of 27 kDa size.
Aggregation with thrombin also induced about 10% degradation
of Btk after 30 min. Calpain inhibitors prevented Btk degrada-
tion in both. The proteolytic products of the Wiskott^Aldrich
syndrome protein (WASP), a calpain and Btk substrate, and the
27 kDa degradation product of Btk did not redistribute to the
Triton-insoluble cytoskeleton in thrombin-aggregated platelets,
in contrast to the uncleaved proteins. The degradation of Btk and
WASP was independent of their tyrosine phosphorylation status.
These results indicate that Btk is an endogenous substrate for
calpain, the cleavage of which may have functional consequences
in long-term post-aggregation events in platelets. ß 2001 Fed-
eration of European Biochemical Societies. Published by Else-
vier Science B.V. All rights reserved.
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1. Introduction
Bruton’s tyrosine kinase (Btk) is a 77 kDa cytoplasmic ty-
rosine kinase belonging to the Tec family. Present particularly
in B-lymphocytes, it has been implicated, if mutated, in the
causation of X-linked agammaglobulinemia in humans and
X-linked immunode¢ciency in mice [1,2]. Although it shares
a number of structural characteristics with the Src family ki-
nases, it possesses several unique domains such as a pleckstrin
homology (PH) domain, a proline-rich region and a Ras
GTPase-activating protein motif.
Btk has recently been reported to be present in platelets
[3,4] where it is activated downstream of the receptors for
thrombin and collagen, as well as the FcQRIIA receptor [3].
Members of the Src family of protein tyrosine kinases, Syk
and focal adhesion kinase (FAK) are known to be present in
platelets in signi¢cant amounts and their regulation and phys-
iologic functions were studied in detail [5]. While Btk plays a
central role in the development and di¡erentiation of B-lym-
phocytes [6], in the degranulation and cytokine production in
mast cells [7] and, as a dual regulator in apoptosis [8], platelets
are not immunocompetent and have relatively distinct func-
tions related to hemostasis and thrombus formation. The
function of Btk in platelets, thus, remains relatively unknown.
Recently, we have shown that Btk speci¢cally associates with
the actin-based cytoskeleton in an integrin KIIbL3-regulated
manner upon challenge of the platelet thrombin and FcQRIIA
receptors [9], suggesting that Btk is a component of a signal-
ing complex containing speci¢c cytoskeletal proteins in acti-
vated platelets. The calcium-dependent thiol proteases cal-
pains are highly expressed in human platelets [10,11] and
are important regulators of signaling events in platelets, in-
cluding clot retraction [12] and microvesicle shedding [13]. As
the active form of calpain has also been reported to associate
with the cytoskeleton of activated platelets [14], we asked
whether calpains could regulate Btk function. Interestingly,
both Btk and its substrate, the Wiskott^Aldrich syndrome
protein (WASP), were found to be degraded by calpain in a
similar fashion in either thrombin- or calcium ionophore-
stimulated platelets. Furthermore, the degradation products
of both were distributed to the Triton-soluble supernatant.
2. Materials and methods
2.1. Materials
Polyclonal antibodies against Btk (sc-1107), FAK (sc-557), SHP-1
(sc-287) and horseradish peroxidase-labeled secondary antibodies were
purchased from Santa Cruz (Santa Cruz, CA, USA). The anti-WASP
rabbit polyclonal antibody (503) was described previously [15]. The
Super Signal West Pico chemiluminescent substrate was from Pierce
(Rockford, IL, USA). Human thrombin, apyrase, EGTA, sodium
orthovanadate, acetylsalicylic acid, bovine serum albumin fraction
V, Triton X-100, leupeptin, pepstatin A, aprotinin, phenylmethylsul-
fonyl £uoride, dimethylsulfoxide (DMSO) and HEPES were pur-
chased from Sigma (St. Louis, MO, USA). A23187 and calpeptin, a
cell permeable inhibitor of calpain, were from Biomol (Plymouth
Meeting, PA, USA). Tween 20 was obtained from Bio-Rad (Rich-
mond, CA, USA). Calpain inhibitor Z-Leu-Abu-CONH-(CH2)3-4-
morphoniyl was a gift from Dr. James Powers, Georgia Institute of
Technology. The reagents for electrophoresis were procured from Sis-
co Research Laboratory and Spectrochem, India. All other reagents
were of analytical grade.
2.2. Platelet preparation
Blood from volunteers was collected in citrate^phosphate^dextrose
and centrifuged at 180Ug for 20 min. Platelet-rich plasma was incu-
bated with 1 mM acetylsalicylic acid and 0.15 ADPase units of apyr-
ase/ml for 15 min at 37‡C. After addition of citric acid (9 mM) and
EDTA (5 mM), platelets were pelleted by centrifugation at 800Ug for
15 min. They were resuspended in bu¡er A (20 mM HEPES, 138 mM
NaCl, 2.9 mM KCl, 1 mM MgCl2, 0.36 mM NaH2PO4, 1 mM
EGTA, supplemented with 5 mM glucose and 0.6 ADPase units of
apyrase/ml, pH 6.2). Platelets were ¢nally resuspended in bu¡er B (pH
7.4), which was the same as bu¡er A, but without EGTA and apyrase.
The ¢nal cell count was adjusted to 0.8^1.2U109/ml.
2.3. Platelet activation and aggregation
Platelets were stirred at 37‡C in a Chrono-log platelet ionized cal-
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cium aggregometer (model 600) for 2 min prior to the addition of
agonists. Platelets were aggregated with thrombin (1 U/ml) or A23187
(1 WM) in the presence or absence of extracellular calcium (2 mM)
under constant stirring (1000 rpm). In some experiments, calcium was
chelated with EGTA (5 mM) 1 min before the addition of the agonist.
In other experiments, platelets were preincubated at 37‡C with either
calpeptin (30 WM) or Z-Leu-Abu-CONH-(CH2)3-4-morphoniyl
(50 WM) for 30 or 15 min, respectively, prior to the addition of the
agonist in the absence of stirring. Aggregation was measured from the
change in light transmission. Control platelets were incubated with
DMSO at concentrations similar to A23187, calpeptin or Z-Leu-
Abu-CONH-(CH2)3-4-morphoniyl. The cells were lysed in the sample
bu¡er supplemented with 5 mM EGTA and 5 mM EDTA in order to
inhibit calpain activity during cell lysis.
2.4. Isolation of detergent lysates of platelets
Platelets were lysed by one-seventh volume of 8U Triton lysis bu¡-
er (1U lysis bu¡er consisting of 1% Triton X-100, 50 mM Tris^HCl,
5 mM EGTA, 5 mM EDTA, 1 mM sodium orthovanadate, 10 WM
leupeptin, 1 mM phenylmethylsulfonyl £uoride, 10 WM pepstatin A
and 0.28 trypsin inhibitor unit/ml aprotinin, pH 7.5). After brief vor-
texing and keeping on ice for 10 min, samples were spun at 16 000Ug
for 20 min at 4‡C in a microcentrifuge. The pellets (Triton-insoluble
cytoskeleton) were washed without resuspension in 1U Triton lysis
bu¡er and ¢nally solubilized in 1U sample bu¡er by heating at 95‡C
for 10 min.
2.5. Immunoblotting of platelet proteins
Platelet proteins were separated on 10% SDS^PAGE gels and elec-
trophoretically transferred to Immobilon-P polyvinylidene £uoride
(PVDF) membranes (Millipore Corp., Bedford, MA, USA) by using
the Nova Blot semidry system as per manufacturer’s instructions. The
membranes were blocked with 10% bovine serum albumin in 10 mM
Tris^HCl, 150 mM NaCl, pH 8.0, containing 0.05% Tween 20 for 2 h
at room temperature. The blots were then incubated for 2 h with
di¡erent dilutions of primary antibodies as follows: goat anti-Btk,
1:750 or rabbit anti-WASP, 1:1000 or rabbit anti-SHP-1, 1:1000 or
rabbit anti-FAK, 1:500. Following washing, the blots were incubated
for 1 h with horseradish peroxidase-labeled anti-goat IgG (1:15 000)
for Btk or anti-rabbit IgG (1:5000 for WASP or 1:12 000 for SHP-1
or 1:15 000 for FAK). The antibody binding was detected using en-
hanced chemiluminescence and bands were quanti¢ed using an Agfa
Duoscan T1200 £atbed scanner and GeneTools software (Syngene,
UK). To quantify actin, proteins were separated by SDS^PAGE,
transferred onto the PVDF membrane and stained with Coomassie
blue. Immunoblots shown are representative of at least three di¡erent
experiments.
3. Results
3.1. Btk is completely cleaved in a calpain-dependent manner in
calcium ionophore-stimulated platelets
Stimulation of platelets with ionophore A23187 (1 WM) in
the presence of extracellular calcium (2 mM) under stirring
conditions induced platelet aggregation. This was associated
with the disappearance of the 77 kDa Btk band from the cells
and concomitant appearance of a new degradation product, a
27 kDa protein, recognized by an antibody against the car-
boxy terminus of the human Btk. The disappearance of Btk
from the blot was completed within 5 min (Fig. 1). Degrada-
tion of Btk was also observed in A23187-treated (1 WM) plate-
lets in the absence of stirring (not shown). However, degra-
dation of Btk and appearance of the proteolytic product was
prevented when calcium was excluded from the bu¡er B or
when EGTA (5 mM) was added to chelate extracellular cal-
cium (data not shown). Under similar experimental condi-
tions, we also detected degradation of SHP-1 (Fig. 1), FAK
(data not shown) and WASP (Fig. 2, right panel) using spe-
ci¢c antibodies, con¢rming previous ¢ndings [16^18]. The ki-
netics of degradation of these proteins paralleled that of Btk.
In order to understand whether calpain was responsible for
the calcium-mediated degradation of Btk, we preincubated the
platelets with either calpeptin [19,20] or Z-Leu-Abu-CONH-
(CH2)3-4-morphoniyl [21,22], cell permeable inhibitors of cal-
pains. Calpeptin (30 WM) or Z-Leu-Abu-CONH-(CH2)3-4-
morphoniyl (50 WM), concentrations su⁄cient to induce inhi-
bition of the calpains, were e¡ective in completely preventing
degradation of Btk (Fig. 2, left panel) and WASP (Fig. 2,
right panel and data not shown) in ionophore-stimulated
platelets. As the cells were lysed in the sample bu¡er supple-
mented with 5 mM EGTA and 5 mM EDTA, chances of
calpain-mediated proteolysis during cell lysis was ruled out.
3.2. Btk is partially cleaved in a calpain-dependent manner in
thrombin-aggregated platelets
As calcium ionophores are not physiological agonists for
platelets, we next sought whether thrombin, a natural platelet
Fig. 1. Btk is degraded in ionophore-treated platelets. Washed plate-
lets were incubated with ionophore A23187 (1 WM) for 30 s (lane
2), 1 min (lane 3), 2 min (lane 4), and 5 min (lane 5) in presence of
2 mM calcium, followed by lysis with the sample bu¡er. Platelet
proteins were separated by SDS^PAGE, transferred onto the PVDF
membranes and immunoblotted using an antibody against Btk
(upper panel) or SHP-1 (middle panel). The lower panel shows the
corresponding actin bands following Coomassie staining. Lane 1:
resting platelets.
Fig. 2. Ionophore-induced degradation of Btk and WASP is inhib-
ited by calpain inhibitors. Washed platelets were treated with
A23187 (lanes 1^3 and 5^6) for 5 min in presence of calcium as de-
scribed in the legend to Fig. 1. Platelets were preincubated with cal-
pain inhibitors as follows: lanes 1 and 2, calpeptin (60 WM and
30 WM, respectively); lane 5, Z-Leu-Abu-CONH-(CH2)3-4-morpho-
niyl (50 WM). Platelets were lysed in sample bu¡er and probed for
Btk (left panel) and WASP (right panel). Degradation products of
WASP are indicated by asterisks. Lanes 4 and 7: resting platelet ly-
sates (without ionophore treatment). Blots corresponding to lanes
1^4 and 5^7 are from di¡erent experiments.
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agonist, was also able to induce Btk proteolysis. When plate-
lets were aggregated with thrombin (1 U/ml) for 5 min in the
presence of extracellular calcium (2 mM), no Btk degradation
was observed (Fig. 3). This is in striking contrast to another
substrate, PTP-1B, which degrades very quickly by calpain in
thrombin-aggregated or ionophore-treated platelets [23,24].
Thrombin, however, induced detectable degradation of Btk
after 15 min, with about 10% degradation after 30 min of
stimulation (Fig. 3). This was associated with appearance of
a 27 kDa proteolytic product. Interestingly, similar kinetics of
degradation were observed with WASP, which was also about
10% degraded after 30 min of thrombin-induced aggregation
(not shown), with the appearance of major degradation prod-
ucts at the 27, 32 and 38 kDa regions [18]. When platelets
were stimulated for 30 min in the absence of stirring we did
not detect any degradation of Btk, thus implicating the signals
elicited by platelet aggregation with Btk proteolysis. Preincu-
bation of platelets with calpeptin (30 WM) completely pre-
vented proteolysis of Btk and subsequent appearance of the
27 kDa band (Fig. 4). Thus, Btk was also cleaved in a calpain-
dependent way in thrombin-aggregated platelets. Preincuba-
tion of platelets with another cell permeable calpain inhibitor,
Z-Leu-Abu-CONH-(CH2)3-4-morphoniyl, [21,22] at 50 WM
concentration was equally e¡ective in inhibiting the limited
proteolysis of both Btk (Fig. 4) and WASP in thrombin-ag-
gregated platelets (not shown).
We have previously demonstrated that Btk is tyrosine-phos-
phorylated after 2 min of thrombin receptor activation and
the phosphorylated state is maintained for 15 min [9]. As
another calpain substrate, SHP-1, is resistant to calpain activ-
ity in the tyrosine-phosphorylated state [16], we asked whether
tyrosine-phosphorylated Btk could be a substrate of calpain.
Platelets were aggregated with thrombin for 2 min in the
presence of extracellular calcium and then exposed to
A23187 or DMSO for a further 5 min under constant stirring.
As expected, thrombin treatment alone for 7 min had negli-
gible e¡ect on the amount of Btk. Interestingly, thrombin
followed by A23187 treatment induced degradation of Btk
similar in extent to platelets treated with ionophore alone,
thus suggesting that tyrosine-phosphorylated Btk was amena-
ble to calpain-mediated proteolysis (Fig. 5). Consistent with
an earlier report [16], we did not detect any cleavage of SHP-1
under similar conditions, while WASP, which is also tyrosine-
phosphorylated downstream of thrombin activation [18], was
degraded similar to Btk (data not shown).
Fig. 3. Degradation of Btk in thrombin-aggregated platelets.
Washed platelets were stimulated with thrombin (1 U/ml) in pres-
ence of extracellular calcium (2 mM) for the indicated time periods
under constant stirring (lanes 2^4) and in absence of stirring (lane
5). Platelets were lysed by sample bu¡er and probed for Btk as
mentioned before.
Fig. 4. Degradation of Btk in thrombin-aggregated platelets is inhib-
ited by calpain inhibitors. Washed platelets were aggregated with
thrombin (1 U/ml) in presence of calcium (2 mM) for 30 min (lanes
2^4, 6 and 7). Platelets were preincubated with either calpeptin (30
WM) for 30 min (lane 7) or Z-Leu-Abu-CONH-(CH2)3-4-morphoniyl
(50 WM, lane 3 and 190 WM, lane 4) for 15 min or DMSO (lanes 2
and 6) before addition of thrombin. Platelets were lysed in sample
bu¡er and probed for Btk as mentioned before. The 27 kDa degra-
dation product is shown separately in the lower panel. Resting
platelet lysates: lanes 1 and 5.
Fig. 5. Calpain-mediated degradation of Btk occurs independent of
tyrosine phosphorylation status. Washed platelets in presence of cal-
cium (2 mM) were aggregated with thrombin (1 U/ml) alone for
7 min (lane 2) or with thrombin for 2 min followed by ionophore
A23187 (1 WM) for a further 5 min (lane 3) or with ionophore
A23187 (1 WM) alone for 5 min (lane 4). Platelets were lysed in
sample bu¡er and probed for Btk as mentioned before. The 27 kDa
degradation product is shown separately in the middle panel. The
lower panel shows the corresponding actin bands following Coomas-
sie staining. Resting platelet lysate: lane 1.
Fig. 6. Degradation products of Btk and WASP are recovered from
the Triton-soluble fraction of thrombin-aggregated platelets. Washed
platelets were aggregated with thrombin (1 U/ml) in the presence of
calcium (2 mM) for the indicated time intervals. Platelets were lysed
with Triton lysis bu¡er. The cytoskeletal (CSK, lanes 1^3) fractions
and Triton-soluble (TS, lanes 4^6) fractions were isolated and pro-
teins were separated by SDS^PAGE and immunoblotted using a
polyclonal anti-Btk antibody (left panel) or anti-WASP antibody
(right panel). The corresponding degradation products are indicated
by asterisks.
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3.3. Degradation products of Btk and WASP are recovered
from the Triton-soluble fraction of thrombin-aggregated
platelets
We have recently shown that Btk redistributes to the actin-
based cytoskeleton in thrombin-aggregated platelets in an in-
tegrin KIIbL3-regulated manner [9]. In order to ¢nd out the
functional implication of Btk proteolysis, we studied the dis-
tribution of its 27 kDa degradation product in activated plate-
lets. When platelets were aggregated with thrombin in the
presence of extracellular calcium, Btk associated with the ac-
tin-based cytoskeleton and this association was maintained
until 30 min. However, the 27 kDa degradation product was
detected only in the Triton-soluble fraction upon prolonged
stimulation for 30 min (Fig. 6, left panel). WASP, which also
translocated to the actin-based cytoskeleton in thrombin-ag-
gregated platelets [18], was found to remain associated with
the cytoskeleton at 30 min. Similar to Btk, the degradation
products of WASP were also detected in the Triton-soluble
supernatant only, and did not translocate to the cytoskeleton
(Fig. 6, right panel).
4. Discussion
We present here evidence showing that Btk is a substrate
for calpain in platelets. Both calpain [14] and Btk [9] are
known to translocate to the cytoskeletal fraction of throm-
bin-stimulated platelets and undergo activation in an integrin
KIIbL3-dependent manner. During activation, the 80 kDa sub-
unit of W-calpain undergoes autoproteolytic conversion to a 78
kDa ‘intermediate’ and a 76 kDa fully autolysed form [25,26],
which are endowed with distinct substrate speci¢cities and
functional roles [24]. The initial conversion to the 78 kDa
form has been implicated with the cleavage of PTP-1B, while
both the 78 and 76 kDa enzymes are responsible for subse-
quent degradation of Src in thrombin-aggregated platelets.
Interestingly, WASP, a Btk substrate [27], also associates
with the cytoskeleton of thrombin-stimulated platelets [18]
and is cleaved by calpain [18]. The kinetics of degradation
of both Btk and WASP are strikingly similar and suggest
them to be possible substrates of the fully cleaved 76 kDa
form of W-calpain.
A 27 kDa degradation product of Btk was recovered from
the Triton-soluble supernatant of the thrombin-aggregated
platelets. A recent study indicated that Btk interacts with
the ¢lamentous actin through a basic 10-residue stretch within
the PH domain (at the amino terminal end of Btk) [28]. As the
antibody used in this study was directed against the carboxy
terminus of Btk, this could explain the absence of the 27 kDa
proteolytic fragment from the actin-rich cytoskeleton. The
calpain-induced degradation products of Src [29] and WASP
also distribute to the supernatant, while the cleaved form of
PTP-1B remains associated with the cytoskeleton [30]. Pre-
liminary in silico analysis and comparison with the consensus
sequence for calpain proteolysis [10] indicates the possible site
of degradation to be after Y461 in the Btk sequence.
With the existing data, we cannot formally rule out the
possibility of activation of other proteases downstream of
calpain-promoting Btk cleavage. A growing number of cyto-
skeletal signaling enzymes and structural proteins have been
identi¢ed as calpain substrates [16^18,23,29^34]; the physio-
logical signi¢cance of these proteolytic events in platelets has
not been well established. Our data suggest that Btk is parti-
ally cleaved by calpain when platelets are aggregated for 30
min with thrombin. In the physiological context, intravascular
platelet clots continue to be exposed to the agonists like
thrombin in their immediate microenvironment long after ag-
gregation. The ensuing activation of calpain causes proteolysis
of molecules like Btk, WASP and Src at a temporally distinct
phase, and this could have important implications in the post-
aggregation events. The 78 kDa form of W-calpain is associ-
ated with the reduction in platelet-mediated clot retraction
[24], while the 76 kDa form appears to regulate the post-li-
gand binding events like shedding of procoagulant-rich mem-
brane microvesicles [24]. Considering the fact that Btk could
play important roles during apoptosis in other cells [8], it is
tempting to speculate that calpain-mediated proteolysis of Btk
might be functionally related to microvesicle shedding (which
simulates membrane blebbing) in platelets as part of platelet
destruction.
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